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Abstract 
Introduction: Nitric oxide (NO) is a compound with both protective and damaging 
effects on neurons. Quantification of NO metabolites in humans is limited by 
sample contamination with blood. In vivo cerebral microdialysis may offer an 
alternative approach as sampling of extracellular fluid (ECF) adjacent to neurons 
becomes possible. We investigate the prognostic value of brain ECF NO 
metabolites in patients with traumatic brain injury (TBI).  
Methods: A prospective case cohort of 195 ECF samples collected from 11 
cases over four days following TBI were collected. Nitrate and nitrite 
concentration ([NOx])  were quantified using a  vanadium based colorimetric 
assay. 
Results:  Early ECF NOx levels (<48 hours post TBI) were significantly higher in 
non-survivors (median 59.2 μmol/L, n=7) compared to survivors (23.3 μmol/L, 
n=4)(p=0.04). Late (48-96 hours) ECF NOx levels remained higher in non-
survivors  47.9 μmol/L compared to survivors 23.0 μmol/L  but this was not of 
significant (p=0.29). Receiver operator characteristic analysis show an optimized 
cutoff level for ECF NOx of 26.5 μmol/L measured <48 hours post TBI for 
predicting non-survival (sensitivity 100%, specificity 75%). 
Conclusion: Early ECF NOx levels are of prognostic value after TBI. ECF NOx 
may be a useful biomarker for treatment trials targeted at nitric oxide metabolism. 
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 INTRODUCTION 
Nitric oxide (NO) is a free radical involved in diverse physiological and 
pathophysiological processes in the central nervous system. After traumatic brain 
injury (TBI), NO may have both protective and damaging effects(1) and this 
relates to NO’s role in cerebral blood flow regulation(2), its reaction with 
superoxide to form peroxynitrite, and its inhibition of cytochrome c oxidase(3). 
TBI remains the major cause of death in young people and survival of TBI is 
associated with significant morbidity. Improved prognostication after TBI might 
facilitate patient selection for aggressive management strategies, which may 
improve mortality but carry the risk of increased morbidity if patient selection is 
suboptimal. 
Due to its short half life, it is difficult to measure nitric oxide concentration 
directly, but measurement of the concentration of downstream NO metabolites, 
nitrate and nitrite (NOx), is an accepted method of estimating endogenous NO 
production(4). NOx concentration ([NOx]) in the cerebrospinal fluid (CSF) of 
patients after TBI has been reported (5,6) but the presence of subarachnoid 
hemorrhage, as commonly occurs after TBI, can influence CSF [NOx] 
measurement(4) and might reduce the usefulness of CSF [NOx] as a marker of 
secondary injury. 
  Cerebral microdialysis is an established technique that allows focal 
measurement of brain extracellular fluid (ECF) biochemistry(7,8). As the 
microdialysis catheter is placed in brain tissue, it can be used to assess [NOx] 
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closer to NO’s site of action than that measured in CSF and localise the 
measurement to a particular area of interest. Microdialysate [NOx] in the brains 
of rats post cortical impact injury correlates well with direct NO electrode 
readings(1). 
In this study we measure the concentration of nitrite and nitrate in the 
brain extracellular fluid of patients with traumatic brain injury and compare it with 
patient outcome.  
 
2. Materials and Methods 
2.1 Patients and sample preparation 
This study was approved by the Joint Research Ethics Committee of the 
National Hospital for Neurology and Neurosurgery and the Institute of Neurology 
and, as all patients were unconscious at the time of the study, written assent was 
obtained from their personal representatives.  
We studied eleven adults with TBI undergoing protocolised management 
to control cerebral perfusion pressure (CPP) and intracranial pressure (ICP) on 
the neurocritical care unit. The patients were all male with median age 26.5 years 
(range 17-68). As part of routine clinical monitoring of brain ECF biochemistry  
each patient had a commercially available microdialysis catheter (CMA 70, 
CMA/Microdialysis, Solna, Sweden) with a 10 mm dialysis membrane length and 
20 kDa molecular weight cut-off inserted into their brain tissue through a skull 
bolt (Technicam Ltd, Newton Abbott, UK).  Probe positioning followed the 
recommendations of the consensus meeting on microdialysis in neurointensive 
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care(9). The probe was perfused with artificial CSF (Perfusion Fluid CNS, CMA), 
using a CMA 106 pump, at a rate of 0.3 µL/min. 
Systemic data including CCP and ICP were collected electronically. After 
routine measurement of standard microdialysis variables, including 
lactate:pyruvate ratio (LPR), using the CMA 600 analyser (CMA/Microdialysis, 
Solna, Sweden), the microdialysate samples were stored at -80 oC prior to NOx 
assay. 
Microdialysate sampling was continued until invasive intracranial 
monitoring was no longer clinically indicated and at that stage the microdialysis 
catheter was removed. In any event only samples from the first 4 days post injury 
were included in this analysis. Peak CSF [NOx] occurs within the first 48 hours 
post TBI(5,6) and so samples for analysis were divided into those taken up to 48 
hours, and those taken 48-96 hours, post TBI. 
2.2 NOx Assay 
We used a vanadium-based assay for nitrite/nitrate measurement in 
biological specimens as described by Miranda et al.(10).  
Reagents: Sulfanilamide (SULF), N-(1-Napthyl) ethyl-enediamine dihydrochloride 
(NEDD), vanadium (III) chloride (VCI
3
), sodium nitrite, sodium nitrate, 
hydrochloric acid were purchased from Sigma-Aldrich (Poole, Dorset, UK). Water 
was purified with Milli-RO and Millli-Q systems (Millipore). 
The assay was performed in a standard flat-bottomed 96-well polystyrene 
microtitre plate, containing 50 μl/well of standard or sample in duplicate. 
Immediately before commencing the assay, Griess reagents: SULF(50μl) and 
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NEDD(50μl) were premixed and added to each well. Nitrite mixed with Griess 
reagents forms a chromophore from the diazotization of sulfanilamide by acidic 
nitrite followed by coupling with bicyclic amines such as N-1-(Napthyl) 
ethylenediamine. Subsequently, the vanadium solution was added in a volume of 
100 μl/well, the contents mixed vigorously and the plate left to incubate for 60 
minutes at 37 oC. The absorbance at 540 nm was measured to assess the total 
level of nitrite and nitrate (NOx) in the samples. 
2.3 Statistical Analysis 
Data were analysed using SAS software (version 9.1, SAS Institute, Cary, 
NC, USA). Wilcoxon rank sum test was used to compare variables in survivors 
and non-survivors. Because of a non-Gaussian distribution the median 
(interquartile range) are presented.  Receiver operator characteristic (ROC) 
analyses are used to determine the sensitivity and specificity of threshold 
variable values for non-survival. Two tailed exact p values are presented 
throughout and values of less than 0.05 are considered significant.  
 
3. Results 
195 microdialysate samples were analysed from 11 patients.  
Microdialysate [NOx] <48 hours post TBI was significantly higher in non-survivors 
(n=7, 59.2 (31.8-150.6) μmol/l compared to survivors 23.3 (15.2-32.9) μmol/l 
(n=4, p=0.04).  Microdialysate [NOx] 48 to 96 hours post TBI was 23.0 
(21.8-35.2) in survivors (n=4) and 47.9 (37.6-60.6) in non-survivors  (n=5) 
(p=0.29) (figure 1). There was no significant difference in microdialysate [NOx] 
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over time for either subgroup although there was a trend toward microdialysate 
[NOx] increasing over time in survivors and decreasing over time in non-
survivors. For the period <48 hours post TBI, receiver operator characteristic 
(ROC) analysis revealed microdialysate [NOx]>26.5 μmol/l predicted non-survival 
with sensitivity 100% and specificity 75% and the area under the curve was 0.89. 
For the period 48-96 hours post TBI microdialysate [NOx]>24.1 μmol/l predicted 
non-survival with sensitivity 100% and specificity 75% and the area under the 
curve was 0.75 (figure 2). 
There were no significant differences in ICP, CPP or microdialysate 
lactate pyruvate ratio between survivors and non-survivors for either time period.  
 
4. Discussion 
This prospective study shows that it is feasible to reliably quantify NOx 
from minute amounts of human ECF using a rapid and high throughput 
technique. The main finding of this study is that ECF NOx samples in the initial 
48 hours after TBI were of prognostic value. This data is in line with results from 
CSF [NOx] in humans after TBI (5). The main advantage ECF NOx levels have 
over CSF NOx levels is that sample contamination with systemic NOx levels 
coming from the blood is less likely.  
The potential of this measurement is suggested by the fact that we saw 
significant differences in microdialysate [NOx] between the outcome groups in 
the period <48 hours post TBI whilst finding no differences in other measured 
variables. ROC analysis indicates effective discrimination between survivors and 
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non-survivors for microdialysate [NOx] <48 hours post TBI as indicated by the 
large area under the ROC plot. Interestingly this overlaps with the time interval of 
accelerated neuronal loss following TBI(8). 
Our results suggest that microdialysate [NOx] might be a useful prognostic 
marker after TBI and that its prognostic value may be greatest early after injury, 
during the first 48 hrs in this study. This is important because if prognostication of 
patient outcome is to guide clinical decision making it must be possible to do so 
as soon as possible after TBI.  
This study presents data from a small number of patients and the 
threshold value we suggest must therefore be viewed as a preliminary result. We 
present these results to demonstrate the prognostic potential of microdialysate 
[NOx] and for evaluation in future studies. These microdialysate concentrations 
are dependent on the relative recovery of NOx and hence the microdialysis 
catheter type and perfusate flow rate and in this study we use standard 
methods(7). Automatisation of the colorimetric method(10) used should be 
possible and thus allow for high throughput bedside measurements of ECF NOx 
levels from much larger patient cohorts. 
The incidence of mortality after TBI in our cohort is high and we believe 
that this is related to our selection of patients for cerebral microdialysis 
monitoring. In our centre, patients in whom sedation is stopped shortly after 
admission following either conservative or surgical management are not 
monitored using cerebral microdialysis and this study cohort therefore represents 
the more severely injured end of the spectrum of our TBI admissions. 
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Microdialysate [NOx] has been previously correlated with regional cerebral 
blood flow in patients with TBI(2). In the above study no significant correlation 
was found between microdialysate [NOx] and neurological outcome, which is in 
apparent contrast with earlier results reported by the same group where the 
highest microdialysate [NOx] in the first 5 days after TBI were found in patients 
surviving with moderate or severe disability as opposed to non-survivors or those 
making a good recovery, with non-survivors having lower microdialysate [NOx] 
than survivors(11).  This seems to be at variance with our findings, perhaps 
reflecting the complexity of NO’s neuroprotective and neurotoxic roles, although 
our results are more consistent with previous CSF studies (5). 
Animal and human studies suggest that the peak in NO occurring > 6 
hours post TBI is primarily related to expression of inducible nitric oxide synthase 
(iNOS)(1) and, as none of our patients were studied <6 hours post TBI, the 
elevated microdialysate [NOx] we observed in non-survivors may also to be due 
to iNOS.  Most studies suggest that NO produced by iNOS has detrimental 
effects and that inhibition of iNOS activity after TBI might have benefit(1), 
although this is not universally accepted. The present findings are in line with the 
basic science literature.  
We would like to stress that, as NO is required for a number of vital 
physiological functions, any future treatment aiming to completely block NO 
production or receptor binding is likely to have deleterious effects. However, 
combining ECF NOx levels with a validated biomarker for neurodegeneration 
(eNfH)(8) might allow determination of the in vivo concentration at which 
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neurotoxicity occurs and thus help establish a target treatment threshold for NOx 
lowering strategies. 
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Figure Legends 
Figure 1: Microdialysate nitrite/nitrate concentration ([NOx]) for survivors and 
non-survivors of traumatic brain injury for the periods less than 48 hours, and 48-
96 hours, post traumatic brain injury (ns=not significant). 
 
Figure 2: Receiver operator characteristic analysis for microdialysate 
nitrite/nitrate concentration ([NOx]) as predictor of non-survival during the first 48 
hours (A) and 48-96 hours (B) post traumatic brain injury. 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Figure 1
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